Saturday 17 October 2026
Export NCNA’s income statement to Excel — free account
NuCana PLC Sponsored ADR
NCNA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 16,379.7% and free cash flow grew 55.7%, each against the same quarter a year earlier.
0.99
0.03
−2.94%
Follow NCNA
NuCana PLC Sponsored ADR (NCNA) P/E ratio
NuCana PLC Sponsored ADR has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DRMA Dermata Therapeutics, Inc. compare | n/m |
| LIMN Liminatus Pharma Inc. compare | n/m |
| NCNA NuCana PLC Sponsored ADR | n/m |
| ADTX Aditxt, Inc. compare | n/m |
| LNAI Lunai Bioworks Inc. compare | n/m |
| JUNS Jupiter Neurosciences, Inc. compare | n/m |
| ENLV Enlivex Ltd. compare | 0.0× |
| AZTR Azitra, Inc. compare | 1.0× |
| PCSA Heatwurx Inc. compare | 1.6× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)